Nightstar was a leading clinical-stage gene therapy company focused on developing and commercialising novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness.
Nightstar was one of Syncona’s first gene therapy companies and was a leading clinical-stage gene therapy company focused on developing and commercialising novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness.
Creating, building, scaling a company through to value realisation
Sold to Biogen in 2019 for $877m
£255.7m proceeds
72% IRR
4.5x multiple of cost
- Syncona partnered with Robert Maclaren, a Professor of Ophthalmology at Oxford to found the business in 2013
- In the space of six years, Nightstar progressed from an academic programme at Oxford University led by a single academic to a publicly listed company at the cutting edge of gene therapy and leader in its field
- Set-up with the intent of global success – both in terms of its ambition to take its products all the way to market itself, and also in the way it was funded
- Importantly, Syncona’s long-term, high conviction approach to financing the business ultimately enabled it to build the platform and team from the start that would allow it to develop a successful, globally competitive biotech company
- Syncona invested £57m in the business and was the sole investor at the £16m Series A financing, investing in each round after, including at the IPO and follow-on financing
- This strategy and the company’s subsequent success has ultimately culminated in Nightstar’s acquisition by Biogen for $877 million in March 2019
Other previous portfolio portfolio companies
